BlueCrest Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

BlueCrest Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,000	Closed	-$304K	–	281
2023 Q1	$304K	Buy	+3,000	New	+$312K	0.01%	209
2019 Q4	–	Sell	-3,895	Closed	-$351K	–	506
2019 Q3	$351K	Buy	+3,895	New	+$364K	0.02%	332
2018 Q4	–	Sell	-21,468	Closed	-$2.64M	–	1223
2018 Q3	$2.64M	Buy	+21,468	New	+$2.44M	0.07%	201
2018 Q1	–	Sell	-17,176	Closed	-$1.33M	–	1586
2017 Q4	$1.33M	Sell	17,176 -8,005	-32%	-$546K	0.04%	333
2017 Q3	$1.54M	Buy	25,181 +13,081	+108%	+$690K	0.06%	288
2017 Q2	$557K	Buy	+12,100	New	+$587K	0.02%	570
2016 Q4	–	Sell	-4,529	Closed	-$229K	–	806
2016 Q3	$229K	Sell	4,529 -3,044	-40%	-$152K	0.01%	645
2016 Q2	$344K	Sell	7,573 -15,462	-67%	-$712K	0.01%	646
2016 Q1	$911K	Buy	+23,035	New	+$914K	0.06%	397

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlueCrest Capital Management's NBIX Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 3,000 shares — an estimated $304K sold.

BlueCrest Capital Management first reported a position in NBIX in Q1 2016 and held it in 9 quarters. The position peaked at $2.64M in Q3 2018. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

BlueCrest Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
BlueCrest Capital Management sold 3,000 Neurocrine Biosciences shares in Q2 2023, an estimated $304K.
BlueCrest Capital Management first reported a position in Neurocrine Biosciences in Q1 2016 and held it in 9 quarters.
BlueCrest Capital Management's Neurocrine Biosciences position peaked at $2.64M in Q3 2018.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.